The estimated Net Worth of John K Bakewell is at least $86.8 Tisíc dollars as of 24 May 2023. Mr. Bakewell owns over 14,400 units of Xtant Medical Inc stock worth over $47,963 and over the last 9 years he sold XTNT stock worth over $38,880. In addition, he makes $0 as Director at Xtant Medical Inc.
John has made over 1 trades of the Xtant Medical Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 14,400 units of XTNT stock worth $38,880 on 24 May 2023.
The largest trade he's ever made was selling 14,400 units of Xtant Medical Inc stock on 24 May 2023 worth over $38,880. On average, John trades about 720 units every 0 days since 2015. As of 24 May 2023 he still owns at least 77,988 units of Xtant Medical Inc stock.
You can see the complete history of Mr. Bakewell stock trades at the bottom of the page.
John K. Bakewell serves as Director of the Company. He is a consultant to the medical technology industry. Mr. Bakewell served as the Chief Financial Officer of Exact Sciences Corporation, a molecular diagnostics company, from January 2016 to November 2016. Mr. Bakewell previously served as the Chief Financial Officer of Lantheus Holdings, Inc., a diagnostic medical imaging company, from June 2014 to December 2015 and as Chief Financial Officer of Interline Brands, Inc., a distributor and direct marketer of broad-line maintenance, repair and operations products, from June 2013 to May 2014. Mr. Bakewell previously was the Executive Vice President and Chief Financial Officer of RegionalCare Hospital Partners, an owner and operator of non-urban hospitals, from January 2010 to December 2011. In addition, Mr. Bakewell held the position of Chief Financial Officer with Wright Medical Group, Inc., an orthopaedic medical device company, from 2000 to 2009, with Altra Energy Technologies, Inc. from 1998 to 2000, with Cyberonics, Inc. from 1993 to 1998 and with Zeos International, Ltd. from 1990 to 1993. Mr. Bakewell has also served as a member of the board of directors of Entellus Medical, Inc., a public medical technology company that designs and manufactures products for the treatment of chronic and recurrent sinusitis in adults and children, since July 2015, and as a member of the board of directors of Corindus Vascular Robotics, Inc., a public medical technology company and the global leader in robotic-assisted vascular interventions, since July 2017. Since July 2008, Mr. Bakewell has served on the board of directors of Keystone Dental, Inc., a private medical device company. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (inactive).
John Bakewell is 56, he's been the Director of Xtant Medical Inc since 2018. There are 3 older and 5 younger executives at Xtant Medical Inc. The oldest executive at Xtant Medical Holdings Inc is Darrel Holmes, 62, who is the Chief Operating Officer.
John's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.
Over the last 9 years, insiders at Xtant Medical Inc have traded over $104,833 worth of Xtant Medical Inc stock and bought 5,164,288 units worth $21,623,047 . The most active insiders traders include Stavros G. Vizirgianakis, Advisors Llc Orbimed a Matthew Rizzo. On average, Xtant Medical Inc executives and independent directors trade stock every 117 days with the average trade being worth of $134,096. The most recent stock trade was executed by Kevin D Brandt on 17 November 2023, trading 41,670 units of XTNT stock currently worth $50,004.
xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.
Xtant Medical Inc executives and other stock owners filed with the SEC include: